Thank you for your interest in the Patient Subtyping Technologies to Drive Therapeutic Efficacy funding opportunity. Since this opportunity requires applying a patient subtyping technology or approach to guide use of an approved therapeutic or development candidate, teaming collaborations between diverse sets of innovators may be needed to achieve these goals.
Teaming
If you or your organization would like to explore collaborations with other potential applicants, please complete the form below. After a short vetting process, you will be contacted be VITAL, and your information will be added to the publicly accessible list below.
Please note that by publishing the teaming profiles list, neither VITAL nor BARDA is endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included. Additionally, completing the form does not constitute an application for the TyPe funding opportunity, but rather, provides you an opportunity to partner and collaborate with other potential applicants to strengthen the quality of the submission.
Submissions to the teaming profiles list are reviewed and updated periodically.
Contact
Organization
Relevant Technology
Potential for Teaming
Our technology is a simulation-based patient subtyping and validation platform that creates virtual human models with customizable organs, genetic traits, and clinical phenotypes. These models allow mechanistic testing of therapeutic responses across diverse patient subgroups, enabling a filtering step before clinical trials. Unlike purely statistical or AI-driven approaches, our platform integrates biological knowledge with real-world data to generate mechanistic predictions, offering insights into why treatments succeed or fail in specific patient populations. By training simulations with retrospective and prospective datasets, we can stratify patients linked directly to therapeutic mechanisms of action, strengthening trial design, improving efficacy readouts, and de-risking development. The system is modular and adaptable, capable of pivoting across BARDA-relevant threats, from pandemic pathogens to severe injury indications, providing a sustainable platform technology. This approach enhances biodistribution and durability assessments by simulating treatment dynamics in silico, reducing development cost, risk, and timelines while improving regulatory credibility.
We are seeking prime contractors and collaborators who can provide the clinical and therapeutic anchors to complement our simulation platform. Specifically, we aim to partner with therapeutic developers (biologics, small molecules, or devices) who have BARDA-relevant products in development or on market, and clinical or diagnostic partners with access to retrospective datasets or prospective patient samples. These partners provide the data and validation channels necessary to tie our simulations directly to therapeutic effects. We are also interested in teaming with diagnostic developers who can translate our virtual subtyping results into measurable biomarkers and regulatory-grade RUO prototypes. In return, we contribute a unique capability: simulation-based validation that generates predictive foresight, reduces trial risk, and accelerates demonstration of therapeutic efficacy. Our ideal partners are organizations that see value in integrating mechanistic modeling with their therapeutic pipeline, enabling stronger BARDA proposals and more efficient paths to approval and commercialization.
Our relevant technologies are:
1: A CAP/CLIA accredited proteomics lab for diagnostic testing & method development.
2: Reverse phase protein array (RPPA) to quantify on and off target therapeutic effects, using antibodies to measure cell signaling proteins and their post-translational modified forms.
3. A patented & commercialized tissue/cell fixative that inactivates viral pathogens and preserves tissue histomorphology and proteins.
4. Laser capture microdissection to procure enriched cell populations from tissue sections.
5. Mass spectrometry for protein sequencing and identification.
6. Protein painting to identify protein hot spot interaction sites.
Potential partners would provide samples for analysis and/or provide complimentary technologies to develop a complete molecular profile of the sample. Example complimentary technologies include microbiome analysis, whole genome sequencing, epigenetic and transcriptomic analyses.
Our platform builds on COMPOSER and COMPOSER-LLM (Nature Digital Medicine) to enable real-time, data-driven phenotyping of sepsis patients. COMPOSER models dynamic physiological trajectories using multimodal EHR data, while COMPOSER-LLM integrates structured and unstructured clinical inputs to refine patient subtypes. These technologies identify latent sepsis phenotypes and map them to historical treatment response patterns. This allows for predictive enrichment in clinical trials and individualized treatment guidance in care settings. By modeling counterfactual outcomes and estimating treatment benefit per phenotype, our platform increases the probability of demonstrating therapeutic efficacy and improves patient outcomes.
We seek partners who bring complementary strengths in therapeutic development, clinical trial execution, and regulatory strategy—especially those committed to precision medicine. We’re particularly interested in teams developing or validating therapies for Sepsis, ARDS or other syndromic conditions where phenotypic heterogeneity limits efficacy.
